ストックスクリーナーアプリを入手
7.35
2.37%
0.17
プレマーケット:
7.59
0.24
+3.27%
Sagimet Biosciences Inc (SGMT) 最新ニュース
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - ca.finance.yahoo.com
Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy - TipRanks
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position - TipRanks
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Will earnings trigger a reversal in Sagimet Biosciences Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
How sentiment analysis helps forecast Sagimet Biosciences Inc.July 2025 Review & Capital Protection Trading Alerts - Newser
Real time scanner hits for Sagimet Biosciences Inc. explained2025 Performance Recap & Real-Time Buy Signal Alerts - Newser
What data driven models say about Sagimet Biosciences Inc.’s futureShare Buyback & High Accuracy Swing Trade Signals - Newser
Is Sagimet Biosciences Inc. stock bottoming outInsider Buying & Free Verified High Yield Trade Plans - Newser
Sagimet Biosciences Inc. recovery potential after sell offWeekly Loss Report & Free Growth Oriented Trading Recommendations - Newser
Screener Results Flag Sagimet Biosciences Inc. as OversoldEarnings Growth Summary & Risk Controlled Stock Alerts - beatles.ru
News impact scoring models applied to Sagimet Biosciences IncEarnings Overview Report & Low Drawdown Trading Techniques - Newser
Is Sagimet Biosciences Inc. building a consolidation baseJuly 2025 Patterns & Fast Entry High Yield Tips - Newser
How high can Sagimet Biosciences Inc. stock price go in 2025Earnings Miss & Real-Time Volume Trigger Notifications - Newser
News impact scoring models applied to Sagimet Biosciences Inc.July 2025 Outlook & Precise Trade Entry Recommendations - Newser
How Sagimet Biosciences Inc. stock performs during market volatilityBull Run & Daily Risk Controlled Trade Plans - Newser
Will Sagimet Biosciences Inc. Benefit From Sector TailwindsTrade Signal Summary & Real-Time Volume Trigger Notifications - metal.it
A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29 - 富途牛牛
Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating - TipRanks
Promising Potential of Sagimet Biosciences’ FASN Inhibitors Drives Buy Rating - TipRanks
Brokers Set Expectations for SGMT Q2 Earnings - Defense World
Sagimet Biosciences Advances FASN Inhibitor Trials for Acne and MASH, Reports Q2 Earnings - AInvest
Sagimet Biosciences Reports Progress in Acne and MASH Trials - TipRanks
Sagimet Biosciences Enters New Sales Agreement with Leerink - TipRanks
Sagimet Biosciences Reports Q2 Results and Clinical Progress - MSN
Sagimet Biosciences enters $75 million at-the-market sales agreement with Leerink Partners - Investing.com Canada
Sagimet Biosciences enters $75 million at-the-market sales agreement with Leerink Partners By Investing.com - Investing.com South Africa
Sagimet Biosciences, Inc. Class A: Promising Combination Therapy for MASH Drives Buy Rating - TipRanks
Sagimet Biosciences Tops Q2 EPS Forecast - AOL.com
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Sagimet Biosciences Q2 GAAP EPS Beats by $0.21, Cash Holdings at $135.5M - AInvest
Sagimet Biosciences: Navigating the High-Risk Biopharma Landscape with Operational Gains and Earnings Resilience - AInvest
Sagimet Biosciences Inc Q2 Loss Increases, But Beats Estimates - Nasdaq
Sagimet Reports Q1 Earnings, Advances Denifanstat and TVB-3567 Trials - AInvest
Sagimet Biosciences Inc. SEC 10-Q Report - TradingView
Wedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT) - Defense World
Sagimet Biosciences Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Wedbush Initiates Sagimet Biosciences at Outperform With $28 Price Target - MarketScreener
Wedbush initiates coverage on Sagimet Biosciences with Outperform rating and $28 PT. - AInvest
Wedbush initiates coverage on Sagimet Biosciences stock with Outperform rating - Investing.com Nigeria
Can Sagimet Biosciences Inc. Escape Recent Bear ChannelDay Trading Signals With High Precision Reviewed - beatles.ru
Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday - Defense World
What is HC Wainwright’s Estimate for SGMT Q2 Earnings? - Defense World
Sagimet Biosciences SGMT Q2 2025 Earnings Preview Upside Potential Driven by Strategic Innovations - AInvest
Sagimet Biosciences (NASDAQ:SGMT) Upgraded at HC Wainwright - Defense World
Is This a Bottoming Phase for Sagimet Biosciences Inc.Capital Protection Trading Strategies Gain Interest - beatles.ru
Can volume confirm reversal in Sagimet Biosciences Inc.Chart Driven Entry Timing for Swing Trades - Newser
Sagimet Biosciences Inc. Matches Institutional Buying FilterWeekly Chart Analysis With Entry Advice Provided - beatles.ru
How to recover losses in Sagimet Biosciences Inc. stockMachine Learning Intraday Signal Forecast - Newser
How to build a dashboard for Sagimet Biosciences Inc. stockShort-Term Upside Breakout Forecast System - Newser
Can Sagimet Biosciences Inc. recover in the next quarterFree Long Hold Safe Return Strategy - Newser
Sagimet Biosciences assumed with a Buy at H.C. Wainwright - TipRanks
Promising Prospects for Sagimet Biosciences: Buy Rating Backed by Innovative FASN Inhibitor Platform and Clinical Advancements - TipRanks
HC Wainwright maintains Buy rating for Sagimet Biosciences with $29 PT. - AInvest
What makes Sagimet Biosciences Inc. stock price move sharplyPre-Market Stock Movement Summary and Review - Newser
1.55%
0.38%
大文字化:
|
ボリューム (24 時間):